Physician profile
Todd Henderson
NPI 1710163050
$5,210.72
in general payments reported to CMS, 2019-2025
36 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $582 · 2021: $398 · 2022: $578 · 2023: $927 · 2024: $933 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.06 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $828.06 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $547.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $479.62 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Insmed, INC. | $425.91 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.20 | 2019-2025 | Ofev |
| Genentech USA, INC. | $335.65 | 2019-2025 | Xolair |
| Merck Sharp & Dohme LLC | $270.70 | 2023-2025 | Winrevair, Recarbrio, Zerbaxa |
| Genzyme Corporation | $265.47 | 2019-2025 | |
| Harmony Biosciences LLC | $217.66 | 2021-2024 | Wakix |
| Mallinckrodt Hospital Products INC. | $188.70 | 2020-2024 | Terlivaz, Acthar |
| Jazz Pharmaceuticals INC. | $176.10 | 2019-2024 | Xywav |
| Zoll Respicardia, INC. | $140.80 | 2023-2024 | Remede System |
| Grifols USA, LLC | $128.13 | 2019-2022 | |
| Mylan Specialty L.P. | $114.34 | 2019-2024 | Yupelri |
| La Jolla Pharmaceutical Company | $104.45 | 2020-2023 | Giapreza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $88.30 | 2024-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $82.64 | 2019-2023 | |
| Electromed, INC. | $70.32 | 2025 | Smartvest |
| United Therapeutics Corporation | $63.66 | 2022-2024 | Tyvaso |
| Gilead Sciences, INC. | $30.95 | 2023 | |
| Amgen INC. | $30.77 | 2022-2023 | Tezspire |
| Shionogi INC | $29.21 | 2023 | Fetroja |
| Novartis Pharmaceuticals Corporation | $24.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.00 | 2022 | |
| Astellas Pharma US INC | $21.93 | 2022 | |
| Intuitive Surgical, INC. | $21.55 | 2022 | |
| Csl Behring | $21.45 | 2020 | |
| Inspire Medical Systems, INC. | $18.03 | 2025 | Inspire |
| Fisher & Paykel Healthcare INC | $17.99 | 2024 | Fisher & Paykel Healthcare |
| Verona Pharma, INC. | $17.38 | 2025 | Ohtuvayre |
| Pfizer INC. | $17.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2023 | Glassia |
| Sunovion Pharmaceuticals INC. | $14.98 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $14.49 | 2019 | |
| Boston Scientific Corporation | $12.72 | 2023 | Exalt Model D |
| Baxter Healthcare | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.